MedTrace Logo

Why Does Aspirin Fail in Secondary Cerebrovascular Prevention? A Multicenter Prospective Case - Control Study

NCT05247931 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-02-21

No results posted yet for this study

Summary

Multicenter prospective observational case-control study aimed at characterizing the possible determinants of treatment failure in patients with cerebrovascular disease on secondary prevention with ASA, who are hospitalized in Internal Medicine departments for a recurrent atherothrombotic stroke.

Conditions

  • Cerebrovascular Disease

Interventions

DIAGNOSTIC_TEST

TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine

Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2

Sponsors & Collaborators

  • Fadoi Foundation, Italy

    lead OTHER

Principal Investigators

  • ANDREA FONTANELLA · FONDAZIONE FADOI

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-07
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05247931 on ClinicalTrials.gov